Loading grant details…
A PROSPECTIVE EUROPEAN VALIDATION COHORT FOR STEREOTACTIC THERAPY OF RE-ENTRANT TACHYCARDIA
| Funder | European Commission |
|---|---|
| Recipient Organization | Christian-Albrechts-Universitaet Zu Kiel |
| Country | Germany |
| Start Date | May 01, 2021 |
| End Date | Apr 30, 2027 |
| Duration | 2,190 days |
| Number of Grantees | 29 |
| Roles | Participant; Coordinator |
| Data Source | European Commission |
| Grant ID | 945119 |
Grant Description
Ventricular tachycardia (VT) is an unpredictable and potentially deadly condition and should be promptly treated with catheter ablation and medication, before irreversible and potentially fatal organ damage follows.
Unfortunately, this combination of treatments does not prevent VT reoccurrence in 30-50% of VT patients and while they can undergo multiple invasive ablations, technical difficulties or refusal of the patient can lead to a lack of effective treatment options. A promising novel, non-invasive treatment option for VT is stereotactic arrhythmia radioablation (STAR).
Besides being non-invasive, STAR can also be used to reach locations that are inaccessible for catheter ablation, which may potentially improve effectiveness of overall VT treatment.Small scale first in men/early phase trials have been performed for STAR, providing proof-of-concept for clinical safety and efficacy.
However, patients with recurrent VT are not a homogenous group and each center deals with different inclusion criteria, imaging and/or target definition.
Many questions remain and the available studies lack the power to clinically validate the approach and prepare for late stage phase III trials.The STOPSTORM consortium sets out to consolidate all current and future European efforts to clinically validate STAR treatment by merging all data in a validation cohort study, standardising pre-treatment and follow-up, in order to collect the data sets and statistical power needed to unanimously establish clinical safety, efficacy and benefit for STAR.
The STOPSTORM consortium also sets out to refine protocols and guidelines, determine volumes of interest, define and model the optimal target region and target dose, also in relation to surrounding healthy tissues (i.e. organs at risk) and determine which patient population and underlying cardiopathies respond best to STAR.
By doing so the STOPSTORM consortium paves the way to consensus and future late stage clinical trials for STAR.
All Grantees
Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie -Panstwowy Instytut Badawczy; Consorcio Mar Parc de Salut de Barcelona; Academisch Ziekenhuis Leiden; Aarhus Universitet; Azienda Unita Sanitaria Locale Di Reggio Emilia; Fondazione Centro Nazionale Di Adroterapia Oncologica; Fondazione Irccs Policlinico San Matteo; Fakultni Nemocnice Ostrava; Fundacion Hospital General Universitario Para la Investigacion Biomedica Docencia Y Desarrollo de Las Ciencias de la Salud; Ruprecht-Karls-Universitaet Heidelberg; Universita Degli Studi Di Torino; Institut Klinické A Experimentální Mediciny; Christian-Albrechts-Universitaet Zu Kiel; Universiteit Maastricht; Insel Gruppe Ag; Servicio Madrileno de Salud; Centre Hospitalier Universitaire Vaudois; Gornoslaskie Centrum Medyczne Im. Prof. Leszka Gieca Slaskiego Uniwersytetu Medycznego W Katowicach; Nemocnice Agel Trinec Podlesi As; Stichting Maastricht Radiation Oncology Maastro Clinic; Universitair Medisch Centrum Utrecht; Stichting Amsterdam Umc; Charite - Universitaetsmedizin Berlin; Aarhus Universitetshospital; Universitat Zurich; Istituto Don Calabria; Universitaet Zu Luebeck; Harteraad; Technische Universitaet Dresden
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
